Mechanistic insight into the other SPM group of the cohort depicted that lung cancer was the most common type of second invasive primary malignancies emerged from BTK inhibitors treatment in the study whereas NMSC was the most common SPM in the ELEVATE‐TN and ASCEND trials. Here, BTK is linked to lung cancer.